女性性的欲求障害治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0918
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2020, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women’s Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 6, 1 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women’s Health).
- The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women’s Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women’s Health)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women’s Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women’s Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Hypoactive Sexual Desire Disorder – Overview
Female Hypoactive Sexual Desire Disorder – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Hypoactive Sexual Desire Disorder – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Hypoactive Sexual Desire Disorder – Companies Involved in Therapeutics Development
Better Life Pharmaceuticals Inc
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
S1 Biopharma Inc
Female Hypoactive Sexual Desire Disorder – Drug Profiles
(buspirone hydrochloride + testosterone) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildenafil citrate + testosterone) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1120 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGSN-005 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Hypoactive Sexual Desire Disorder – Dormant Projects
Female Hypoactive Sexual Desire Disorder – Discontinued Products
Female Hypoactive Sexual Desire Disorder – Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Jun 17, 2019: Daré Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference
Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials
Jan 09, 2018: Emotional Brain’s FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials
Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
May 01, 2015: Emotional Brain Prepares for the Last Stage in Clinical Development of Medicines for Sexual Dysfunction in Women
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Better Life Pharmaceuticals Inc, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by EndoCeutics Inc, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Ivix Ltd, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, H1 2020
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2020
Female Hypoactive Sexual Desire Disorder - Discontinued Products, H1 2020

【掲載企業】

Better Life Pharmaceuticals Inc
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
S1 Biopharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[女性性的欲求障害治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆